- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Marksans Pharma Limited — Updates, 23-09-2025: Press Release
23-09-2025 | 02:18 pm
23-09-2025 | 02:18 pm
Marksans Pharma's UK subsidiary, Relonchem, secured UK marketing authorization for Moxonidine 200 & 400 microgram tablets. This paves the way for commercialization, strengthening its presence in the UK market.
No comments yet. Be the first to comment!